|Bid||2.41 x 3100|
|Ask||2.98 x 4000|
|Day's Range||2.6900 - 2.7800|
|52 Week Range||2.4700 - 9.9250|
|Beta (3Y Monthly)||1.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.32|
Aduro Biotech, Inc. (ADRO) today announced the publication of a peer-reviewed paper in Cell Reports authored by Aduro scientists and Novartis collaborators as part of their ongoing research to study intratumoral stimulator of interferon genes (STING) pathway activation as a potential therapeutic approach for the treatment of cancer. In this study, researchers determined an intratumoral dosing regimen of STING pathway activator, ADU-S100, optimized for adaptive immunity in mouse models. While high doses of ADU-S100 were effective at clearing injected tumors, researchers found that higher tumor ablative dosing regimens could compromise durable anti-tumor immunity.
Aduro Biotech, Inc. (ADRO) today announced preclinical data in two abstracts for its first-in-class anti-APRIL antibody BION-1301 supporting its potential use as a treatment for multiple myeloma (MM) at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. Data from the studies demonstrated that therapies blocking a proliferation inducing ligand (APRIL) from binding to B cell maturation antigen (BCMA) and transmembrane activator and cyclophilin ligand interactor (TACI) may simultaneously target MM cells and APRIL-induced immunosuppression. “Our newest findings from the data presented at ASH indicate that combining an anti-APRIL antibody such as BION-1301, which inhibits APRIL binding to TACI and BCMA, with a BCMA-targeted therapy may have the potential to augment anti-myeloma activity,” commented Dr. Kenneth C. Anderson, director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute.
Aduro Biotech, Inc. (ADRO) today announced presentation of preliminary data from its ongoing Phase 1 dose-finding study of ADU-S100 (MIW815), a novel STING (stimulator of interferon genes) pathway activator, at SITC's 33rd Annual Meeting in Washington, D.C. Aduro and collaborator Novartis embarked on this first-in-human trial (see www.clinicaltrials.gov, identifier NCT02675439) as an important first step in characterizing the safety profile and mechanism of ADU-S100 and its ability to activate the STING pathway. The Phase 1 dose escalation and dose expansion clinical trial is designed to evaluate the safety, tolerability and clinical activity of ADU-S100 in patients with advanced, metastatic treatment-refractory solid tumors or lymphomas.
Aduro Biotech, Inc. (ADRO) today announced that the company will host and webcast an investor event on Friday, November 9, 2018 at 6:30 p.m. Eastern Time in Washington, D.C. The event will feature special guest speaker Jason J. Luke, M.D., FACP, Assistant Professor of Medicine at the University of Chicago and a principal investigator for the Phase 1 dose-finding studies of ADU-S100 (MIW815), a novel STING (stimulator of interferon genes) pathway activator. The archived webcast will remain available for replay on Aduro’s website for 30 days.
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.
Aduro Biotech (ADRO) delivered earnings and revenue surprises of 6.45% and -33.21%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
BERKELEY, Calif., Oct. 30, 2018 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the third quarter ended September 30, 2018. Net loss for the third.
Aduro Biotech, Inc. (ADRO) today announced preclinical data for its first-in-class anti-APRIL antibody BION-1301 supporting its use in the treatment of IgA nephropathy (IgAN) at the American Society of Nephrology (ASN) Kidney Week 2018 in San Diego, CA. IgAN is a progressive kidney disease characterized by an autoimmune antibody response against endogenous IgA. Preclinical studies demonstrated that BION-1301 binds to a specifically defined epitope on APRIL, resulting in complete blockade of APRIL induced receptor activation, and is expected to lead to suppression of IgA and the autoimmune response to IgA associated with the disease.
Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aduro Biotech, Inc. (ADRO) today announced that four separate abstracts from its research and development portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C. from November 7-11, 2018. Preliminary clinical data from the ongoing Phase 1 dose-finding study evaluating ADU-S100 (MIW815), an intratumoral STING agonist in patients with advanced solid tumors or lymphomas, were accepted for presentation on November 9, 2018. “We look forward to sharing preliminary clinical data from the dose escalation portion of the monotherapy trial which provides an initial understanding of the potential role of ADU-S100 in the treatment of cancer and which contribute to the broader scientific understanding of the STING pathway,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro Biotech.
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that are intended to transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.
Aduro Biotech, Inc. (ADRO) today announced that Natalie R. Sacks, M.D. has resigned from her position as the company’s chief medical officer effective October 1, 2018. “On behalf of the management team and Board of Directors, I’m grateful for the significant contributions Natalie made over the past three years and we wish her the best in her next endeavor,” commented Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “During her tenure, Natalie has played an integral role in defining the development strategy for our lead STING agonist ADU-S100 and for our anti-APRIL antibody BION-1301, two first-in-class assets that have potential to impact the treatment landscape for patients with a myriad of serious diseases.
Aduro BioTech (ADRO) needs investors to pay close attention to the stock based on moves in the options market lately.
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. Aduro BioTech’s insiders have divested from 53.11k sharesRead More...
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aduro Biotech (ADRO) delivered earnings and revenue surprises of 6.06% and -29.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Berkeley, California-based company said it had a loss of 31 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...